Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma

被引：0
|
作者：
Zhu, Yihao [1 ]
Li, Yajian [1 ]
Li, Xuwen [1 ]
Yu, Yuan [2 ]
Zhang, Lingpu [3 ,4 ]
Zhang, Hanchen [3 ,4 ]
Chen, Can [5 ]
Chen, Dong [1 ]
Wang, Mingshuai [1 ]
Xing, Nianzeng [1 ]
Yang, Feiya [1 ]
Wasilijiang, Wahafu [1 ,6 ]
Ye, Xiongjun [1 ]
机构：
[1] Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,100021, China
[2] Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Zhejiang,310022, China
[3] Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing,100190, China
[4] University of Chinese Academy of Sciences, Beijing,100049, China
[5] Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Guizhou,563000, China
[6] Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi,030013, China
来源：
Advanced Healthcare Materials | 2024年 / 13卷 / 32期
关键词：
Tumors;
D O I：
10.1002/adhm.202402973
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prognostic value of CD147 and HIF-2α expression in localized clear cell renal cell carcinoma
    Li, Hao
    Zhang, Tian
    Zhang, Yang
    Wang, Pei
    Bian, Huijie
    Chen, Zhi-Nan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (09): : 9394 - 9400
  • [42] Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?
    Nogueira, Ines
    Dias, Francisca
    Morais, Mariana
    Teixeira, Ana Luisa
    Medeiros, Rui
    FUTURE ONCOLOGY, 2019, 15 (20) : 2361 - 2370
  • [43] Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)
    McDermott, D. F.
    Choueiri, T. K.
    Bauer, T. M.
    Arrowsmith, E.
    Roy, A.
    Perini, R.
    Vickery, D.
    Tykodi, S. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S681 - S681
  • [44] Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Bauer, Todd Michael
    Merchan, Jaime R.
    Papadopoulos, Kyriakos P.
    McDermott, David F.
    Michaelson, M. Dror
    Appleman, Leonard Joseph
    Thamake, Sanjay
    Zojwalla, Naseem J.
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] NADPH OXIDASE 4 MEDIATES NUCLEAR TRANSLOCATION OF HIF-2α VIA GENERATION OF INTRACELLULAR SUPEROXIDE IN HUMAN RENAL CELL CARCINOMA CELLS
    Turner, Robert
    Chang, Guimin
    Chen, Li
    Maranchie, Jodi
    JOURNAL OF UROLOGY, 2012, 187 (04): : E64 - E64
  • [46] PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
    Wallace, Eli M.
    Cao, Zhaodan
    Cheng, Tzuling
    Czerwinski, Robert
    Dixon, Darryl D.
    Du, Xinlin
    Goggin, Barry
    Grina, Jonas
    Halfmann, Megan
    Han, Guangzhou
    Huang, Heli
    Josey, John A.
    Maddie, Melissa A.
    Olive, Sarah
    Rizzi, James
    Schlachter, Stephen T.
    Tan, Hui-Ling
    Wang, Bin
    Wang, Keshi
    Wehn, Paul M.
    Xie, Shanhai
    Xu, Rui
    Yang, Hanbiao
    CANCER RESEARCH, 2015, 75
  • [47] INHIBITION OF MTOR/AKT PATHWAY ENHANCES CELL DEATH VIA AUTOPHAGY IN RENAL CELL CARCINOMA
    Chen, Hua
    Potts, Kyle
    Murray, Allan
    Moore, Ronald
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1167 - E1167
  • [48] Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
    Maeva Dufies
    Annelies Verbiest
    Lindsay S. Cooley
    Papa Diogop Ndiaye
    Xingkang He
    Nicolas Nottet
    Wilfried Souleyreau
    Anais Hagege
    Stephanie Torrino
    Julien Parola
    Sandy Giuliano
    Delphine Borchiellini
    Renaud Schiappa
    Baharia Mograbi
    Jessica Zucman-Rossi
    Karim Bensalah
    Alain Ravaud
    Patrick Auberger
    Andréas Bikfalvi
    Emmanuel Chamorey
    Nathalie Rioux-Leclercq
    Nathalie M. Mazure
    Benoit Beuselinck
    Yihai Cao
    Jean Christophe Bernhard
    Damien Ambrosetti
    Gilles Pagès
    Communications Biology, 4
  • [49] Targeting HIF2α with an RNAi therapeutic for the treatment of clear cell renal cell carcinoma
    Nicholas, A.
    Wong, S.
    Zhu, R.
    Carlson, J.
    Frankiewicz, A.
    Shu, D.
    Hamilton, H.
    Schienebeck, C.
    Andersen, A.
    Fowler-Watters, M.
    Bertin, S.
    Liu, C.
    Li, X.
    Chen, B.
    Schumacher, J.
    Hegge, J.
    Given, B.
    Li, Z.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E9 - E9
  • [50] Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α
    Fan, Yang
    Li, Hongzhao
    Ma, Xin
    Gao, Yu
    Bao, Xu
    Du, Qingshan
    Ma, Minghui
    Liu, Kan
    Yao, Yuanxin
    Huang, Qingbo
    Zhang, Yu
    Zhang, Xu
    ONCOTARGET, 2016, 7 (14) : 18280 - 18294
12345